DBPR108

SKU: orb1308401

Description

DBPR108 is an orally active, dipeptide-based DPP4 inhibitor with an IC50 of 15 nM, demonstrating high selectivity as it does not inhibit DPP8 or DPP9. This compound is a valuable research tool for investigating DPP4 function in metabolic diseases, including diabetes, in both in vitro enzymatic assays and in vivo pharmacological studies.

Research Area

Protein Biochemistry

Key Properties

• CAS Number: 1186426-66-3
• MW: 324.39
• Purity: 99.68% (May vary between batches)
• Formula: C₁₆H₂₅FN₄O₂
• SMILES: CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N
• Target: DPP-4
• Solubility: DMSO:≥ 25 mg/mL (77.07 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (6.17 mM)

Bioactivity

• In Vivo:
  DBPR108 is a potent, selective, long-acting and safe DPP-IV inhibitor as a potential treatment of type 2 diabetes mellitus. The in vivo effects of DBPR108, including inhibition of plasma DPP-IV activity and suppression of blood glucose elevation, were also demonstrated.
  Read more...
• In Vitro:
  DBPR108 displays a more than 3000-fold selectivity over DPP8 DPP9, FAP and DPP-II.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Dipeptidyl Peptidase, DPP-4, DPP4, DPP, inhibit, Inhibitor, DBPR108, DBPR-108, DBPR 108

Compound Identifiers

PubChem CID

44201003